Posted by Michael Wonder on 07 Nov 2023
Germany, Belgium and France among those hit hardest as Commission’s Pharma-legislation proposals risk Europe losing a third of its share of global R&D by 2040
6 November 2023 - The European Federation of Pharmaceutical Industries and Associations (EFPIA) is publishing new research which assesses the impact of the European Commission’s draft Pharmaceutical Legislation on Europe’s competitiveness, the future of its innovative life-science sector and patient care.
While the Commission has committed to carrying out a European competitiveness check on future legislation it has not done so for the pharmaceutical legislation. Considering its impact on one of Europe’s largest and most strategically significant industries, EFPIA commissioned the Dolon consultancy to undertake a comprehensive competitiveness check on the proposed legislation.
